Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellatio

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Bu

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to J

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and low

/PRNewswire/ -- Before the opening bell today, ArriVent BioPharma (NASDAQ: AVBP) shares were already

Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy

U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led

Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowe

BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the

AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed

ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million c

ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endp

Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday&#3

U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong resu

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) reached a new 52-week low during trading o

U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. U

NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given a consensus recommendation

Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the u

The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progress

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus r

Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Bu

Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) b

NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent

Affinity Asset Advisors LLC lifted its position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP)

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulat

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommend

US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and s

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investor

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in